Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System

Annalisa Lattanzi, Stephanie Duguez, Arianna Moiani, Araksya Izmiryan, Elena Barbon, Samia Martin, Kamel Mamchaoui, Vincent Mouly, Francesco Bernardi, Fulvio Mavilio, Matteo Bovolenta

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)
156 Downloads (Pure)


Exonic duplications account for 10-15% of all mutations in Duchenne muscular dystrophy (DMD), a severe hereditary neuromuscular disorder. We report a CRISPR (Clustered Regularly Interspaced Short Palindromic Repeat)/Cas9-based strategy to correct the most frequent (exon 2) duplication in the DMD gene by targeted deletion, and tested the efficacy of such an approach in patient-derived myogenic cells. We demonstrate restoration of wild-type dystrophin expression at transcriptional and protein level in myotubes derived from genome-edited myoblasts in the absence of selection. Removal of the duplicated exon was achieved by the use of only one gRNA directed against an intronic duplicated region, thereby increasing editing efficiency and reducing the risk of off-target effects. This study opens a novel therapeutic perspective for patients carrying disease-causing duplications.
Original languageEnglish
Pages (from-to)11-19
Number of pages8
JournalMolecular Therapy - Nucleic Acids
Early online date7 Mar 2017
Publication statusPublished (in print/issue) - 16 Jun 2017


  • Correction of the DMD exon 2
  • CRISPR/Cas9


Dive into the research topics of 'Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System'. Together they form a unique fingerprint.

Cite this